EUVIMEDEUVIMED entdecken
Crossref

Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US

Ibrahim Halil Sahin, Yan Lin, Greg Yothers, Peter C Lucas, Dustin Deming, Thomas J George, Scott Kopetz, Christopher H Lieu, Arvind Dasari

ONCOLOGY · 12.10.2022 · (3610) · 604-608

DOI: 10.46883/2022.25920976 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ONCOLOGY, online erschienen am 14.10.2022. Verfasst von Ibrahim Halil Sahin und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Colonic Neoplasms, Pancreatic Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The ability to detect circulating tumor DNA (ctDNA), a novel surrogate for minimal residual disease (MRD) for patients with solid tumors, has significantly evolved over the past decade. Several studies have shown that ctDNA may provide clinical insight into the biological dynamics of MRD. The CIRCULATE-US (NRG-GI008; NCT05174169) trial will aim to address the role of ctDNA for risk stratification to intensify and deintensify adjuvant chemotherapy for patients with early-stage colon cancer. METHODS: CIRCULATE-US, a prospective phase 2/3 randomized trial, is investigating the molecular dynamics and prognostic role of ctDNA (evaluated by Natera’s Signatera assay) for patients with resected colon cancer. Patients with negative postoperative ctDNA will be enrolled in cohort A and randomized to receive either immediate treatment with 5-fluorouracil and folinic acid or capecitabine plus oxaliplatin (FOLFOX6 or CAPEOX; Arm 1) or serial ctDNA surveillance with delayed adjuvant therapy (Arm 2). Patients randomized to Arm 2 with subsequent positive ctDNA results will be enrolled in cohort B for a second randomization to receive either FOLFOX6/CAPEOX (Arm 3) or 5-fluorouracil, folinic acid, oxaliplatin, and irinotecan (FOLFIRINOX; Arm 4) for 6 months. Patients with positive postoperative ctDNA results will be directly enrolled in cohort B and randomized to receive either FOLFOX6/CAPEOX (Arm 3) or FOLFIRINOX (Arm 4). Patients with stage II or stage IIIC colon cancer with positive ctDNA results (tested as standard of care with commercial testing) will be eligible for enrollment in cohort B. The primary end point for cohort A is time to positive ctDNA status for phase 2 and disease-free survival for phase 3 with a noninferiority design. The primary end point for cohort B is disease-free survival for both phase 2 and phase 3 with a superiority design. DISCUSSION: CIRCULATE-US will aim to understand postoperative ctDNA dynamics in early-stage colon cancer and will investigate escalation and de-escalation approaches by using ctDNA status as a surrogate for MRD status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAColonic NeoplasmsPancreatic NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsCapecitabineFluorouracilIrinotecanLeucovorinNeoplasm, ResidualOrganoplatinum CompoundsOxaliplatinProspective StudiesClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicEquivalence Trials as Topic

Substanzen

CapecitabineCirculating Tumor DNAFluorouracilIrinotecanLeucovorinOrganoplatinum CompoundsOxaliplatin

Zitieren

APA

Sahin, I. H., Lin, Y., Yothers, G., Lucas, P. C., Deming, D., George, T. J., Kopetz, S., Lieu, C. H., & Dasari, A. (2022). Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. ONCOLOGY, 604-608. https://doi.org/10.46883/2022.25920976

Vancouver

Sahin IH, Lin Y, Yothers G, Lucas PC, Deming D, George TJ, et al. Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. ONCOLOGY. 2022:604-608. doi:10.46883/2022.25920976

BibTeX
@article{Sahin2022,
  author = {Sahin, Ibrahim Halil and Lin, Yan and Yothers, Greg and Lucas, Peter C and Deming, Dustin and George, Thomas J and Kopetz, Scott and Lieu, Christopher H and Dasari, Arvind},
  title = {Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US},
  journal = {ONCOLOGY},
  year = {2022},
  number = {3610},
  pages = {604--608},
  doi = {10.46883/2022.25920976}
}
Kostenlos starten →